Navigation Links
Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
Date:2/28/2008

MONTVALE, N.J., Feb. 28 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced today that it will report its fourth quarter and full year 2007 financial results on Thursday, March 6, 2008, before the U.S. financial markets open. Management will provide a Company update and discuss the financial results during a conference call on Thursday, March 6, 2008, at 9:00 a.m. EST.
Investors and other interested parties may access the call as follows:

Date: Thursday, March 6, 2008

Time: 9:00 a.m. EST

Telephone (U.S.): 800.599.9829

Telephone (international): 617.847.8703

Participant Passcode: 91069592

Webcast: http://www.memorypharma.com under the

"Investors" section

An audio replay of the conference call will be available from 11:00 a.m. EST on Thursday, March 6, 2008, until Thursday, March 13, 2008. To access the replay, please dial 888.286.8010 (U.S.) or 617.801.6888 (international) and enter pass code number 63677090. An audio replay of the conference call will also be available under the "Investors" section of the Company's website during the same period.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and, schizophrenia. For additional information, please visit our website at http://www.memorypha
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
2. Scientists synthesize memory in yeast cells
3. Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster
4. Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster
5. Scientists synthesize memory in yeast cells
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants
8. ASU researchers improve memory devices using nanotech
9. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
10. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
11. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... the Day 180 List of Outstanding Issues (LOI) from ... Human Use (CHMP) for the NB32 Marketing Authorization Application ... is an investigational drug candidate being evaluated for weight ... Day 120 time point were adequately addressed by the ...
(Date:7/30/2014)...  AtheroNova Inc. (OTCBB: AHRO), a biotech company ... to safely regress atherosclerotic plaque and improve lipid ... CardioNova, has accomplished first dosing of subjects for ... compound, AHRO-001.  This Phase 1b trial will be ... trial completed in February 2014, in which patients ...
(Date:7/30/2014)... July 30, 2014 Vala Sciences ... U.S. Environmental Protection Agency (EPA). This new contract ... toxicity models, including tests designed to assess the ... the formation of connections between neurons (synapses), which ... and synapse formation by environmental pollutants likely contributes ...
(Date:7/29/2014)... July 30, 2014 SoundConnect ... collaboration company, is proud to announce the strategic ... positions in their Boston, Charleston and Atlanta offices. ... the increased demand for hosted solutions, collaboration and ... and reduce cost. , SoundConnect was founded in ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3SoundConnect Organization and Culture is Evolving 2
... July 14 Bio-Optronics, Inc., a leader in healthcare workflow ... software solution that can simultaneously handle the most intricate scheduling ... staff schedules. , , Physician ... , Bio-Optronics President & CEO, ...
... , HALIFAX, NS, July 14 /PRNewswire/ - ImmunoVaccine ... entered into an agreement to exclusively license seven ... company. These proprietary antigens specifically target breast, ovarian ... antigens with its DepoVax(TM) delivery platform to develop ...
... , , TAMPA, Fla., July ... on the research and development of cancer immunotherapies, announces that the ... its dendritic cell therapy. , , ... I/II clinical trial testing the safety and efficacy of its immunotherapy ...
Cached Biology Technology:NEW Momentum(TM) Physician and Staff Scheduling Software for Imaging Centers, OB/GYN, and Other Specialty Practices Improves Productivity and Equity in Scheduling 2ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 3
(Date:7/30/2014)... biologists, led by Clemson University associate professor Andrew S. ... will pave the way for novel anti-fouling paint for ... and industrial applications. , The team,s findings, published in ... larval stage of barnacles that attaches to a wide ... material that acts as an underwater heavy-duty adhesive. , ...
(Date:7/30/2014)... Portland Press Limited today announced an across-the-board increase ... , The 2013 InCites Journal Citation Reports (Thomson ... Biochemical Journal , Essays in Biochemistry ... Bioscience Reports all received increases in their ... Biochemical Society and published by Portland Press Limited. ...
(Date:7/30/2014)... A professor from Wayne State University,s College of ... National Science Foundation for the project, "Nanoparticle-directed synthesis ... National Science Foundation, nanotechnology is the creation and ... novel properties and functions. A major bottleneck in ... methods that connect different functional materials into one ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... have created the first three-dimensional living tissue model, complete ... therapeutics to combat brain tumors. The 3-D model gives ... tissue cultures. The researchers created a glioma, or ... surrounds it. In a series of experiments, the team ...
... have succeeded in changing the genetic material of cancer ... in nanosurgery opens the door to new medical applications, ... A light scalpel to treat cancerous cells, The ... team uses a femtosecond laser (a laser with ultra-short ...
... Resolving the world,s major challenges whether climate change, ... scarcity requires a sweeping shift in our approach ... leading scientists told European policy makers today during ... and Societal Challenges for our Unstable Earth" (RESCUE). ...
Cached Biology News:Researchers make living model of brain tumor 2Europe needs a 'RESCUE' revolution 2Europe needs a 'RESCUE' revolution 3